Total Payments
$148,437
2024 Payments
$10,041
Companies
40
Transactions
762
Medicare Patients
8,981
Medicare Billing
$831,216
Payment Breakdown by Category
Other$126,555 (85.3%)
Food & Beverage$13,642 (9.2%)
Travel$7,223 (4.9%)
Consulting$900.00 (0.6%)
Education$116.66 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $126,555 | 50 | 85.3% |
| Food and Beverage | $13,642 | 671 | 9.2% |
| Travel and Lodging | $7,223 | 20 | 4.9% |
| Consulting Fee | $900.00 | 2 | 0.6% |
| Education | $116.66 | 19 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amarin Pharma Inc. | $52,553 | 96 | $0 (2022) |
| Amgen Inc. | $31,763 | 92 | $0 (2024) |
| Kowa Pharmaceuticals America, Inc. | $19,260 | 81 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $17,039 | 26 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $11,486 | 41 | $0 (2023) |
| Boston Scientific Corporation | $8,794 | 61 | $0 (2024) |
| Medicure Pharma Inc. | $2,911 | 5 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $1,225 | 103 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $479.07 | 58 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $338.27 | 23 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,041 | 99 | Amgen Inc. ($8,847) |
| 2023 | $3,024 | 62 | Boston Scientific Corporation ($1,402) |
| 2022 | $9,301 | 68 | Amgen Inc. ($8,060) |
| 2021 | $14,773 | 91 | Amgen Inc. ($11,779) |
| 2020 | $11,066 | 79 | Amarin Pharma Inc. ($6,998) |
| 2019 | $28,457 | 119 | Amarin Pharma Inc. ($18,539) |
| 2018 | $16,142 | 95 | Regeneron Healthcare Solutions, Inc. ($5,807) |
| 2017 | $55,631 | 149 | Amarin Pharma Inc. ($26,356) |
All Payment Transactions
762 individual payment records from CMS Open Payments — Page 1 of 31
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $16.56 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/09/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $11.16 | General |
| Category: Cardiology | ||||||
| 11/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $4.80 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $122.99 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/21/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $20.45 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/19/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: Obesity | ||||||
| 11/06/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $12.16 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/06/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $5.45 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $11.84 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/05/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $0.72 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/04/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $14.67 | General |
| 10/30/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/22/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $18.05 | General |
| Category: Cardiology | ||||||
| 10/22/2024 | Kerecis Limited | Kerecis Omega3 SurgiClose (Device), Kerecis Omega3 Marigen, Kerecis Omega3 Marigen | Food and Beverage | Cash or cash equivalent | $14.70 | General |
| Category: Wound Care | ||||||
| 10/15/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.45 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/14/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $14.47 | General |
| Category: Obesity | ||||||
| 10/10/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/10/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $0.72 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/08/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $13.27 | General |
| 10/07/2024 | CVRx, Inc. | Barostim Neo System (Device) | Food and Beverage | Cash or cash equivalent | $25.54 | General |
| Category: Heart Failure and Hypertension | ||||||
| 09/30/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $14.02 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 09/24/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/20/2024 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Cardiology | ||||||
| 09/18/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $18.59 | General |
| Category: Cardiovascular | ||||||
| 09/17/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 2,369 | 3,098 | $921,670 | $213,612 |
| 2022 | 16 | 2,293 | 3,045 | $875,900 | $207,346 |
| 2021 | 20 | 2,517 | 3,323 | $939,995 | $246,542 |
| 2020 | 18 | 1,802 | 2,392 | $696,345 | $163,716 |
Total Patients
8,981
Total Services
11,858
Medicare Billing
$831,216
Procedure Codes
72
All Medicare Procedures & Services
72 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 600 | 1,091 | $473,140 | $106,855 | 22.6% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 249 | 254 | $179,010 | $41,439 | 23.1% |
| 93882 | Ultrasound of one side of head and neck blood flow | Office | 2023 | 172 | 172 | $77,710 | $17,705 | 22.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 69 | 112 | $38,455 | $11,392 | 29.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 87 | 107 | $33,020 | $7,882 | 23.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 512 | 656 | $32,800 | $7,771 | 23.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 35 | 35 | $22,350 | $5,188 | 23.2% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 68 | 68 | $17,235 | $4,204 | 24.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 24 | 24 | $13,525 | $3,236 | 23.9% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 356 | 381 | $11,430 | $2,606 | 22.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 23 | 23 | $5,275 | $1,278 | 24.2% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 68 | 68 | $4,995 | $1,165 | 23.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 12 | $2,870 | $811.68 | 28.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 14 | 14 | $4,330 | $798.41 | 18.4% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 68 | 68 | $3,400 | $768.95 | 22.6% |
| 93784 | Ambulatory blood pressure monitoring, 1 day or longer, with recording, scanning analysis, interpretation, and report | Office | 2023 | 13 | 13 | $2,125 | $511.30 | 24.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 561 | 1,061 | $460,935 | $106,683 | 23.1% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 259 | 268 | $191,140 | $46,978 | 24.6% |
| 93882 | Ultrasound of one side of head and neck blood flow | Office | 2022 | 112 | 113 | $51,900 | $12,418 | 23.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 486 | 616 | $30,800 | $7,158 | 23.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 52 | 80 | $26,780 | $7,157 | 26.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 83 | 95 | $29,360 | $6,938 | 23.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 34 | 34 | $22,040 | $5,712 | 25.9% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2022 | 483 | 555 | $16,650 | $3,885 | 23.3% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2022 | 44 | 44 | $11,220 | $2,849 | 25.4% |
About Dr. Nathaniel Lebowitz, M.D
Dr. Nathaniel Lebowitz, M.D is a Cardiovascular Disease healthcare provider based in Fort Lee, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1063418994.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nathaniel Lebowitz, M.D has received a total of $148,437 in payments from pharmaceutical and medical device companies, with $10,041 received in 2024. These payments were reported across 762 transactions from 40 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($126,555).
As a Medicare-enrolled provider, Lebowitz has provided services to 8,981 Medicare beneficiaries, totaling 11,858 services with total Medicare billing of $831,216. Data is available for 4 years (2020–2023), covering 72 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Fort Lee, NJ
- Active Since 06/24/2005
- Last Updated 06/25/2010
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1063418994
Products in Payments
- Vascepa (Drug) $52,553
- Repatha (Biological) $31,651
- Livalo (Drug) $19,260
- PRALUENT (Drug) $16,967
- PRALUENT ALIROCUMAB INJECTION (Biological) $10,318
- WATCHMAN (Device) $7,327
- HMG-CoA reductase inhibitor (Drug) $1,800
- WATCHMAN Access System (Device) $1,429
- PRALUENT (Biological) $1,151
- ZYPITAMAG (Drug) $1,100
- LEQVIO (Drug) $761.40
- XARELTO (Drug) $479.07
- ELIQUIS (Drug) $473.16
- ENTRESTO (Drug) $463.77
- Veltassa (Drug) $291.99
- Barostim Neo System (Device) $209.85
- BYSTOLIC (Drug) $141.64
- VERQUVO (Drug) $113.84
- NEXLETOL (Drug) $108.04
- JARDIANCE (Drug) $98.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Fort Lee
Mohammed Gibreal, M.d, M.D
Cardiovascular Disease — Payments: $21,101
Cardiovascular Disease $21,101
Steve Kim, Md, MD
Cardiovascular Disease — Payments: $9,218
Cardiovascular Disease $9,218
Dr. Jacqueline Hollywood, M.d, M.D
Cardiovascular Disease — Payments: $5,524
Cardiovascular Disease $5,524
Dr. Diane Zanger, M.d, M.D
Cardiovascular Disease — Payments: $5,307
Cardiovascular Disease $5,307
Dr. Howard Rothman, M.d, M.D
Cardiovascular Disease — Payments: $4,276
Cardiovascular Disease $4,276
Dr. Walter Berkowitz, M.d, M.D
Cardiovascular Disease — Payments: $2,906
Cardiovascular Disease $2,906